Slide 1: AFT Pharmaceuticals Investor Presentation May 2018
AFT PHARMACEUTICALS Investor Presentation May 2018 Investor Presentation May 2018
Slide 2: Important Notice
IMPORTANT NOTICE This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New Zealand dollars (NZ$)
Slide 3: Current Highlights
CURRENT HIGHLIGHTS 125 countries that Maxigesic is licensed in – up from 110 at the end of FY2017 10 countries that Maxigesic is launched and sold in 7 number of clinical studies AFT will have running in FY2019 $81.9m total income for FY2018* $6.8m available cash as at 31 March 2018 * Total income c
Slide 4: Financial Performance – Revenue Growth
FINANCIAL PERFORMANCE – REVENUE GROWTH Operating revenue, FY2005 – FY2018 90 80 Operating revenue (NZ$m) 70 10 year CAGR: 14% 60 50 40 30 20 10 - FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY2017 Operating revenue by region FY2018 Operating revenue by region Southeast Asia
Slide 5: Financial Performance – Revenue by Region and Channel
FINANCIAL PERFORMANCE – REVENUE BY REGION AND CHANNEL Operating revenue by region, FY2016 – FY2018 NZ$000's FY2016 % of total FY2017 % of total FY2018 % of total Australia 31,224 48.8% 37,063 53.6% 49,193 61.4% YoY growth 18.7% 32.7% New Zealand 31,135 48.6% 29,167 42.1% 27,095 33.8% YoY growth -6.3
Slide 6: Financial Performance – Summary P&L
FINANCIAL PERFORMANCE – SUMMARY P&L NZ#039;000's year ended 31 March 2018 % of 2017 % of revenue revenue Revenue 80,071 69,205 Cost of Sales (45,880) 57.3% (43,207) 62.4% Gross Profit 34,191 42.7% 25,998 37.6% Other Income 2,235 2.8% 2,659 3.8% Selling and distribution expenses (28,533) 35.6% (25,964)
Slide 7: Financial Performance – Summary Balance Sheet
FINANCIAL PERFORMANCE – SUMMARY Balance Sheet NZ#039;000's year ended 31 March 2018 2017 ASSETS Current Assets Inventories 24,412 22,198 Trade and other receivables 16,954 16,051 Cash and cash equivalents 6,770 15,905 Derivative assets 176 - Total current assets 48,312 54,154 Non-current Assets Propert
Slide 8: Financial Performance – Summary Cashflow
FINANCIAL PERFORMANCE – SUMMARY Cashflow NZ#039;000's year ended 31 March 2018 2017 Net cash used in operating activities (10,904) (19,062) Net cash used in investing activities (5,855) (1,598) Net cash generated from financing activities 7,600 9,042 Net increase in cash (9,159) (11,618) Impact of fore
Slide 9: Advanced Clinical Study Program
ADVANCED CLINICAL STUDY PROGRAM • 7 studies across the AFT portfolio and 900+ patients • 7 countries - Australia, Jordan, Mexico, New Zealand, Russia, United Kingdom, United States • Significant Clinical Trials for Maxigesic oral and IV dose forms are mainly completed • Completed Maxigesic IV pivota
Slide 10: Maxigesic Global Update
Eastern Europe and Balkans – MAXIGESIC GLOBAL UPDATE Nordics – launch pending 4Q 2018 launches pending 2018 Italy – successful launch and BE/LX & FR– launches pending sales growing still 3-4Q18 UK – launched Licensing discussions starting Licensing discussions starting for Russia for USA & Canada IE
Slide 11: Example of Maxigesic Licensee Progress to Date – Tablet Sales per Month
EXAMPLE OF MAXIGESIC LICENCEE PROGRESS TO DATE – tablet sales per month 1,400,000 1,200,000 1,000,000 800,000 600,000 400,000 200,000 - Investor Presentation 10 May 2018
Slide 12: Maxigesic countries launched and launch plan
Maxigesic countries launched and launch plan Investor Presentation 11 May 2018
Slide 13: Maxigesic: Going Forwards
MAXIGESIC: GOING FORWARDS Additional out-licensing and distribution agreements for Maxigesic oral dose forms have been secured to increase the number of countries to 125 from 110. Some additional countries still to be added – Up to about 12 Numerous Maxigesic registrations underway which are require
Slide 14: NasoSURF Nebuliser: Going Forwards
NASOSURF NEBULISER: Going Forwards A handheld ultrasonic nasal mesh nebuliser for the Product intranasal delivery of medication and treatment of description chronic sinusitis The NasoSURF Nebuliser has desirable features over currently marketed nebulisers, which are not approved for delivery of spec
Slide 15: Summary of Medium Term Plans
SUMMARY OF MEDIUM TERM PLANS Key aim is to trade profitably during FY19 Phased launches of Maxigesic in over 110 countries including North America and Europe Add additional Maxigesic dose forms to the initial launches to extend sales Further licensing agreements for Maxigesic and Maxigesic IV in lar